A2 Biotherapeutics
30301 Agoura Road
Suite 210
Agoura Hills
CA
91301
United States
Website: http://www.a2bio.com/
Email: info@a2bio.com
12 articles about A2 Biotherapeutics
-
A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/2/2023
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies, shares new highlights from the BASECAMP-1 ( NCT04981119 ) master pre-screening protocol in an oral presentation Friday, November 3, at the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5, 2023, in San Diego.
-
A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530, a Novel Cell Therapy for the Treatment of Colorectal, Pancreatic and Non-small Cell Lung Cancers
5/30/2023
A2 Biotherapeutics, Inc. today announced the first patient has been dosed in the Phase 1 clinical trial of A2B530.
-
A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022
11/7/2022
A2 Bio today announced four poster presentations will be given on November 10, 2022 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting in Boston, MA.
-
A2 Bio publishes key preclinical findings demonstrating potential of its highly selective Tmod™ cell therapy platform to revolutionize the treatment of solid tumors in select patients
3/2/2022
A2 Biotherapeutics, Inc., a biotechnology company focused on the treatment of solid tumors, announced that key preclinical data related to its proprietary Tmod™ cell therapy platform have been published in Science Translational Medicine and Journal for ImmunoTherapy of Cancer.
-
A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future Tmod™ CAR T Therapy
1/18/2022
A2 Biotherapeutics, Inc. is a biotechnology company focused on the development of a first-in-class, logic-gated Tmod™ CAR T cell therapy platform to tackle the fundamental challenge in solid tumor treatment—the ability of cancer medicines to distinguish between tumor and normal cells.
-
A2 Bio Provides First Preclinical Data Presentation for CEA and MSLN Programs, Including Trial Update at SITC 2021
11/12/2021
A2 Biotherapeutics, Inc., "A2 Bio", is a biotechnology company focused on the development of a first-in-class Tmod™ T cell therapy platform to tackle the fundamental challenge in solid tumor treatment—the ability of cancer medicines to distinguish between tumor and normal cells.
-
A2 Bio to Highlight Program Updates in Two Presentations at SITC 2021
11/1/2021
A2 Biotherapeutics, Inc., "A2 Bio", is a biotechnology company focused on the development of first-in-class T cell therapies to treat solid tumors.
-
Vida Ventures III will approach investments the same way its first two funds do, identifying and investing in what they believe to be transformative biomedical innovative companies.
-
Tempus Announces Companion Diagnostic Collaboration With A2 Biotherapeutics
1/13/2021
Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to develop a companion diagnostic (CDx) test with A2 Biotherapeutics for its new therapy targeting patients with Loss of Heterozygosity (LOH). It is anticipated that this collaboration could also provide a platform for the development of further CDx tests for A2’s other clinical development programs
-
A2 Biotherapeutics Enters Into Collaboration Agreement With Merck To Develop Allogeneic Cell Therapy For Solid Tumor Cancers
12/23/2020
A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for cancer patients with solid tumors, today announced that it has entered into an agreement with Merck,
-
A2 Biotherapeutics Entered Into Collaboration Agreement With Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers
12/23/2020
A2 Biotherapeutics ( www.a2bio.com ), a biotechnology company developing innovative cell therapies for cancer patients with solid tumors, today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, in which A2 will continue research and preclinical development of its undisclosed Tmod™ cell therapy candidate
-
A2 Biotherapeutics Closes $71.5M Series B To Begin Clinical Development Of Its Potentially Transformative Selective Tumor Cell Therapeutics
10/6/2020
A2 Biotherapeutics, a biotechnology company developing innovative cell therapies for solid tumor cancer patients, announced the closing of its $71.5M Series B financing.